stockportfolio.pro
Stocks / BIO vs HQY
BIO vs HQY
Bio-Rad Laboratories, Inc. and HealthEquity, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Bio-Rad Laboratories, Inc. (BIO) | HealthEquity, Inc. (HQY) | |
|---|---|---|
| Market cap | $7.8B | $7.5B |
| Revenue (latest FY) | $2.58B | $1.31B |
| Net income (latest FY) | $759.90M | $215.20M |
| Revenue growth (5y CAGR) | 0.3% | 12.4% |
| Net margin | 29.4% | 16.4% |
| Return on equity | 10.2% | 10.2% |
| P/E ratio | 48.8 | 33.5 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 7 | 8 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open BIO — free Open HQY — freeFrequently asked questions
Which is bigger, BIO or HQY?
Bio-Rad Laboratories, Inc. is larger by market capitalization — $7.8B versus $7.5B.
Which grows faster, BIO or HQY?
Over the last five fiscal years, HealthEquity, Inc. grew revenue faster — 12.4%/yr versus 0.3%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.